Skip to content

Immunome IMNM Change in Lease Liabilities

Change in Lease Liabilities at other companies

SELLAS Life Sciences Group, Inc. logo
SELLAS Life Sciences Group, Inc.SLS
-$159K0.0%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$47K+1,275%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
-$685K+24.1%
Moderna logo
ModernaMRNA
-$7M-40.0%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Revenue--100%
Operating income-$59.3M-32.9%
Net income-$53.8M-29.3%
EPS (diluted)-$0.48+7.7%

Balance sheet

See full
Cash & equivalents$582.7M+126%
Total debt$3.7M-22.6%
Total equity$588.7M+91.7%
Total assets$619.8M+80.9%

Cash flow

See full
Operating cash flow-$58.6M-10.5%
CapEx$3.0M-18.1%
Free cash flow-$61.6M-8.7%

Valuation

See full
Market cap$2.19B+323%
Enterprise value$1.61B+470%
P/S545.2×+498×

Profitability

See full
Operating margin-5,947.9%-12,002pp
Net margin-5,593.8%-11,284pp
FCF margin-5,118.9%-8,601pp

Returns & leverage

See full
Return on equity-50.1%-10.8pp
Debt / equity0.0×
Current ratio21.7×+11.2×

Where this comes from

Reported directly by Immunome in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunome's change in lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immunome's change in lease liabilities?
Immunome (IMNM) reported change in lease liabilities of -$161K in Q1 2026.
How has Immunome's change in lease liabilities changed year-over-year?
Immunome's change in lease liabilities decreased by 159.7% year-over-year, from -$62K to -$161K.
What does change in lease liabilities mean?
Cash payments for operating leases reducing the lease liability, partially offset by new lease commencements.